Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prospective Observational Swiss Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19.
COVID-19 is a coronavirus induced viral pneumonia leading to Acute Respiratory Distress Syndrome. Previous coronavirus infections (SARS and MERS) led to pulmonary fibrosis in up to 30%. Prospective evaluation of lung abnormalities and pulmonary fibrosis after COVID-19 infection is crucial as novel treatments against lung fibrosis of different etiologies are available. No data on pulmonary longterm effects in COVID-19 survivors are currently available. The nation-wide Swiss COVID-19 lung group establishes a meticulously characterized prospective cohort study on pulmonary long-term sequela of patients living in Switzerland.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COVID-19 Lung | COVID-19 survivors in Switzerland |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| COVID-19 | Other | Research project in which biological material is sampled and health-related personal data are collected and used for further research. Coded data are used. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pulmonary follow-up sequelae in patients after COVID-19 | Number of patients with the long-term pulmonary complications by measuring lung function, exercise testing and radiological Imaging | 36 months |
| Evaluation of risk factors for adverse Outcome after COVID-19 | Number of patients with risk factors including comorbidities and other cofactors and correlate them to adverse outcome in patients after COVID-19 | 36 months |
| Measure | Description | Time Frame |
|---|---|---|
| Compare the functional Pulmonary outcome of COVID-19 disease | Compare pulmonary function measurements between mild and moderate to severe and critical COVID-19 disease | 36 months |
| Compare the radiological Pulmonary outcome of COVID-19 disease |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients included are survivors of COVID-19.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Manuela Funke-Chambour, MD | University Hospital Bern, Department of Pulmonary Medicine - Lead Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Claraspital AG - Department of Pulmonary Medicine | Basel | 4002 | Switzerland | |||
| Universtiy Hospital Bern (Inselspital), Department of Pulmonary Medicine - Lead Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37789266 | Derived | Abu Hussein N, Machahua C, Ruchti SC, Horn MP, Piquilloud L, Prella M, Geiser TK, von Garnier C, Funke-Chambour M. Circulating calprotectin levels four months after severe and non-severe COVID-19. BMC Infect Dis. 2023 Oct 3;23(1):650. doi: 10.1186/s12879-023-08653-7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D018352 | Coronavirus Infections |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Coded biological material
|
Compare imaging measurements between mild and moderate to severe and critical COVID-19 disease
| 36 months |
| Quality of Life after COVID-19 | Compare Quality of Life questionnaires between mild and moderate to severe and critical COVID-19 disease | 36 months |
| Physical performance after COVID-19 using Clinical Frailty Scale | To observe and compare the physical performance after COVID-19 via the Clinical Frailty Scale between mild and moderate to severe and critical COVID-19 disease | 36 months |
| Physical performance after COVID-19 using frailty assessment tests | To observe and compare the physical performance after COVID-19 via frailty assessment tests between mild and moderate to severe and critical COVID-19 disease | 36 months |
| Microbiota and COVID-19 | Number of patients with changes in microbiota in response to COVID-19 by microbiota analysis of sputa, bronchoalveolar lavage and swaps | 36 months |
| Bern |
| 3010 |
| Switzerland |
| University and Hospital of Fribourg | Fribourg | 1708 | Switzerland |
| Hôpitaux Universitaires de Genève - Service de Pneumologie | Geneva | 1211 | Switzerland |
| CHUV - Service de Pneumologie | Lausanne | 1011 | Switzerland |
| Clinica Moncucco | Lugano | 6900 | Switzerland |
| Kantonspital St. Gallen - Klinik für Pneumologie und Schlafmedizin Lungenzentrum | Sankt Gallen | 9007 | Switzerland |
| Hôpital du Valais - Service de Pneumologie | Sion | 1950 | Switzerland |
| Universitätsspital Zürich - Klinik für Pneumologie | Zurich | 8091 | Switzerland |
| D014777 |
| Virus Diseases |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |